Benjamin Hadida co-founded Exeliom Biosciences, a clinical-stage biotechnology company based in France in December 2016. He is an entrepreneur who developed a wide range of competences in various industries such as investment banking (UBS), venture capital (Pacific Channel), pharmaceutical regulatory affairs (Amgen), biotech operations (Theravectys) and even applied research at the Vision Institute in Paris. Benjamin has a master’s degree in management (admission sur concours Prépas) from ESSEC Business School and a master’s degree in Molecular and Cellular Biology from Sorbonne University. At Exeliom Biosciences, Benjamin has raised over 24 million euros, in both non-dilutive and dilutive funding, to develop a new class of microbiome-based medicines called Live Biotherapeutics, with applications in Inflammatory Bowel Diseases, Cancer and Infectious Diseases.